This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pellizzon, G. G. Articles by Stone, G. W. Search for Related Content PubMed PubMed Citation Articles by Pellizzon, G. G. Articles by Stone, G. W.

Importance of mitral regurgitation inpatients undergoing percutaneous coronaryintervention for acute myocardial infarction

The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial

Gregory G. Pellizzon, MD^*, Cindy L. Grines, MD, FACC, David A. Cox, MD, FACC, Thomas Stuckey, MD, FACC, James E. Tcheng, MD, FACC^||, Eulogio Garcia, MD^¶, Giulio Guagliumi, MD^#, Mark Turco, MD, FACC^**, Alexandra J. Lansky, MD, FACC, John J. Griffin, MD, FACC, David J. Cohen, MD, FACC, Eve Aymong, MD, Roxana Mehran, MD, FACC, William W. O'Neill, MD, FACC and Gregg W. Stone, MD, FACC^,*

^* Mid-America Heart Institute, Saint Luke's Hospital, Kansas City, Missouri, USA
William Beaumont Hospital, Royal Oak, Michigan, USA
Mid Carolina Cardiology, Charlotte, North Carolina, USA
Moses Cone Memorial Hospital, Greensboro, North Carolina, USA
^|| Duke Clinical Research Institute, Durham, North Carolina, USA
^¶ Hospital Gregorio Maranon, Madrid, Spain
^# Ospedali Riuniti di Bergamo, Bergamo, Italy
^** Washington Adventist Hospital, Tacoma Park, Maryland, USA
Virginia Beach General Hospital, Virginia Beach, Virginia, USA
Beth Israel-Deaconess Medical Center, Boston, Massachusetts, USA
the Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New York, New York, USA

View larger version (13K): [in a new window]   Figure 1 One-year survival stratified by the severity of baseline mitral regurgitation.

View larger version (25K): [in a new window]   Figure 2 Multivariate predictors of one-year mortality.

View larger version (27K): [in a new window]   Figure 3 Impact of randomization to stenting versus balloon angioplasty (pooled regardless of abciximab administration), and to abciximab versus no abciximab (pooled regardless of stent use) on one-year mortality as a function of the severity of baseline mitral regurgitation. Solid bars = percutaneous transluminal coronary angioplasty; open bars = stent; striped bars = no abciximab; checkered bars = abciximab.